Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3261-3280 of 3,900 trials

Severe Asthma: Dupilumab Treatment Study

We are investigating how Dupilumab affects mucus buildup and immune responses in patients with severe asthma. This study aims to improve understanding of asthma management and treatment options.

Severe Asthma>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

Kidney Transplant: Ravulizumab Study

We are testing Ravulizumab in adults at high risk of delayed graft function after kidney transplantation. The goal is to see if it helps improve kidney function and reduces the need for dialysis.

Delayed Graft Function after Kidney Transplantation1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNephrology

5-Aminolevulinic Acid (5-ALA) for Brain Tumors in Kids

We are studying the safety of 5-ALA during surgeries for children and adolescents with brain tumors. The trial will help us understand how well it identifies tumor cells and its effects on young patients.

Brain Tumor>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Advanced Solid Tumors: PM54 Treatment Study

We are testing a new drug called PM54 in patients with advanced solid tumors to see how safe it is and how it works. This study aims to explore new treatment options for those with limited choices.

Selected Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Anesthesia Study: Ketamine vs. Propofol Combinations

We are comparing the effectiveness of ketamine alone and a ketamine-propofol mix against standard propofol for safe tracheal intubation in patients at risk of aspiration during surgery. The goal is to see which option leads to fewer complications and better tolerance.

Rapid Sequence Induction≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry

Duchenne Muscular Dystrophy: ENTR-601-44 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and how it affects muscle function. Participants will receive either the treatment or a placebo in a controlled setting.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Solid Tumors: YL201 Treatment Study

We are investigating a new treatment called YL201 for patients with advanced solid tumors. The goal is to see how effective and safe it is compared to current options.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Lung Surgery: Oxygen Delivery Techniques

We are comparing three methods of oxygen administration during lung surgery to see how they affect recovery and complications. This study aims to find the best approach for improving patient outcomes after surgery.

Lung Resection Surgery>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPulmonology

Central Retinal Artery Occlusion: Tenecteplase Study

We are investigating whether tenecteplase can help improve vision in patients with central retinal artery occlusion when given shortly after symptoms begin. This study compares it to standard treatment to see which is more effective.

Central Retinal Artery Occlusion>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyNeurologyOphthalmology

Cardiovascular Risk: Allopurinol Study

We are investigating if allopurinol can lower cardiovascular risks in patients with high risk, including those experiencing long-COVID. This study focuses on individuals over 60 years old as well.

Heart FailureHypertensionAtrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyEndocrinologyInternal Medicine

Papillary Craniopharyngioma: Dabrafenib and Trametinib Treatment

We are studying how well the medications dabrafenib and trametinib reduce tumor size in patients with papillary craniopharyngioma. The trial also looks at how these treatments affect quality of life and other health aspects.

Papillary Craniopharyngioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Surgery and Immune Response: Low-Dose Interferon-alfa2a Study

We are investigating whether low-dose Interferon-alfa2a can improve immune function and recovery in patients undergoing surgery. This study looks at immune cell changes and recovery quality compared to a placebo.

Colon Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Difficult-to-Treat Hypertension: OPTIMAL-HT Study

We are exploring whether a new combination of medications can help people with uncontrolled high blood pressure achieve better control. This study will compare different treatment strategies to find the most effective approach.

High Blood Pressure (Hypertension)OverpressureConfirmation phase (III)Monitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Managing High Potassium: Lokelma for Chronic Kidney Disease

We are studying whether Sodium Zirconium Cyclosilicate (Lokelma) can help lower potassium levels in patients with chronic kidney disease. This trial compares it to standard treatments to find the best approach.

High Potassium Levels in Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Hidradenitis Suppurativa: Ruxolitinib Cream Study

We are evaluating a new cream for people with hidradenitis suppurativa to see if it helps reduce symptoms and is safe to use. This study aims to find out how effective the cream is compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementDermatology

Asthma Treatment: JNJ-95597528

We are testing a new medication to see if it is safe and how it works in people with mild to moderate asthma. This study will help us understand its effects compared to a placebo.

Mild to Moderate Asthma1-2 yearsSafety phase (I)Internal MedicinePulmonology

Advanced Basal Cell Carcinoma: Cemiplimab Treatment Study

We are studying the effectiveness and safety of Cemiplimab for patients with advanced basal cell carcinoma. This trial aims to see how well it works as a first-line treatment and to identify factors that may affect treatment outcomes.

Basal Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Glioblastoma: Radiodynamic Therapy with 5-Aminolevulinic Acid

We are testing a new treatment combining radiodynamic therapy and 5-Aminolevulinic acid for patients with a first recurrence of glioblastoma. The goal is to find the highest safe dose and ensure it can be tolerated.

Recurrent Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Macitentan Dosing Study in Healthy Adults

We are comparing the effects of two doses of Macitentan on blood vessel function and heart health in healthy participants. This research may help us understand how different doses impact the body.

Pulmonary Arterial Hypertension1-2 yearsSafety phase (I)Cardiology

Prostate Cancer: Short vs. Long-Term Androgen Deprivation Therapy

We are comparing short-term and long-term hormone therapy combined with radiotherapy for men with prostate cancer that has returned after surgery. The goal is to see which approach may improve survival and reduce recurrence.

Prostate Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyUrology